{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:24:48Z","timestamp":1790832288527,"version":"4.1.0"},"reference-count":88,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Public Health Service","award":["U01 CA224182-01"],"award-info":[{"award-number":["U01 CA224182-01"]}]},{"name":"Public Health Service","award":["P50CA2616050"],"award-info":[{"award-number":["P50CA2616050"]}]},{"name":"Shipley Family Foundation"},{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Rodent models for evaluating new cancer immunotherapies often fail to fully recapitulate the complexity of immune interactions that occur in cancer patients. Companion dogs with spontaneously developing cancers more closely resemble humans immunologically than rodents. This resemblance results in part because their immune systems have been educated early by repeated vaccinations and viral and bacterial infections, with further sculpting later in life by tumors that typically take months to develop. Moreover, dogs possess all of the major leukocyte subsets present in humans, both in circulation and within tumor tissues. The major canine cancer models most relevant to evaluating new cancer immunotherapies include osteosarcoma, glioma, non-Hodgkin lymphoma, melanoma, uroepithelial cancer, and head and neck cancers. Each of these cancers recapitulates to varying degrees the genetics, histology, and biological behaviors of the human analogous cancers. Immune therapies under active investigation in companion dogs include chimeric antigen receptor T-cell therapies, myeloid cell\u2013targeted therapies, radioimmunotherapy, and tumor vaccines. Results of these ongoing studies are expected to accelerate the translation to humans of promising therapy combinations, while also identifying approaches that are ineffective or associated with unacceptable immunological toxicities.<\/jats:p>","DOI":"10.1093\/jimmun\/vkaf244","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:01:38Z","timestamp":1761897698000},"page":"2515-2522","source":"Crossref","is-referenced-by-count":8,"title":["Role of companion dogs in cancer immunotherapy development"],"prefix":"10.1093","volume":"214","author":[{"given":"Lyndah","family":"Chow","sequence":"first","affiliation":[{"name":"Flint Animal Cancer Center, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University , Fort Collins, CO,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Ammons","sequence":"additional","affiliation":[{"name":"Flint Animal Cancer Center, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University , Fort Collins, CO,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W","family":"Dow","sequence":"additional","affiliation":[{"name":"Flint Animal Cancer Center, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University , Fort Collins, CO,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2025103104013056700_vkaf244-B1","doi-asserted-by":"crossref","first-page":"E009063","DOI":"10.1136\/jitc-2024-009063","article-title":"Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision","volume":"12","author":"Emens","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2025103104013056700_vkaf244-B2","doi-asserted-by":"crossref","first-page":"E007815","DOI":"10.1136\/jitc-2023-007815","article-title":"Advances and challenges in cancer immunoprevention and immune interception","volume":"12","author":"Stanton","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2025103104013056700_vkaf244-B3","doi-asserted-by":"crossref","first-page":"1428307","DOI":"10.3389\/fonc.2024.1428307","article-title":"The current state and trends of immunotherapy research in lung cancer: a review and bibliometric analysis","volume":"14","author":"Zheng","year":"2024","journal-title":"Front Oncol"},{"key":"2025103104013056700_vkaf244-B4","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nbt0906-1065b","article-title":"The dog as a cancer model","volume":"24","author":"Khanna","year":"2006","journal-title":"Nature Biotechnol"},{"key":"2025103104013056700_vkaf244-B5","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.3389\/fimmu.2019.02935","article-title":"A role for dogs in advancing cancer immunotherapy research","volume":"10","author":"Dow","year":"2019","journal-title":"Front Immunol"},{"key":"2025103104013056700_vkaf244-B6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev-animal-022114-110911","article-title":"Dogs as a model for cancer","volume":"4","author":"Gardner","year":"2016","journal-title":"Annu Rev Anim Biosci"},{"key":"2025103104013056700_vkaf244-B7","doi-asserted-by":"crossref","first-page":"231356","DOI":"10.1098\/rsos.231356","article-title":"The effect of body size and inbreeding on cancer mortality in breeds of the domestic dog: a test of the multi-stage model of carcinogenesis","volume":"11","author":"Nunney","year":"2024","journal-title":"R Soc Open Sci"},{"key":"2025103104013056700_vkaf244-B8","first-page":"67","volume-title":"Progress in molecular biology and translational science","author":"Nance","year":"2022"},{"key":"2025103104013056700_vkaf244-B9","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41568-020-0297-3","article-title":"Improving human cancer therapy through the evaluation of pet dogs","volume":"20","author":"LeBlanc","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"2025103104013056700_vkaf244-B10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tvjl.2010.04.019","article-title":"The creation of the Comparative Oncology Trials Consortium Pharmacodynamic Core: infrastructure for a virtual laboratory","volume":"185","author":"Paoloni","year":"2010","journal-title":"Vet J"},{"key":"2025103104013056700_vkaf244-B11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-3-319-04843-7_13","article-title":"Using canine osteosarcoma as a model to assess efficacy of novel therapies: can old dogs teach us new tricks?","volume":"804","author":"Rodriguez","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"2025103104013056700_vkaf244-B12","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00262-019-02360-6","article-title":"Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy","volume":"68","author":"Tarone","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2025103104013056700_vkaf244-B13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/aac2.12046","article-title":"Increased risk of cancer in dogs and humans: a consequence of recent extension of lifespan beyond evolutionarily-determined limitations?","volume":"3","author":"Sarver","year":"2022","journal-title":"Aging Cancer"},{"key":"2025103104013056700_vkaf244-B14","author":"National Cancer Policy Forum; Board on Health Care Services; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine","year":"2015"},{"key":"2025103104013056700_vkaf244-B15","doi-asserted-by":"crossref","first-page":"1130215","DOI":"10.3389\/fonc.2023.1130215","article-title":"Naturally occurring canine sarcomas: bridging the gap from mouse models to human patients through cross-disciplinary research partnerships","volume":"13","author":"Klosowski","year":"2023","journal-title":"Front Oncol"},{"key":"2025103104013056700_vkaf244-B16","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1038\/s41598-019-40285-3","article-title":"Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells","volume":"9","author":"Goulart","year":"2019","journal-title":"Sci Rep"},{"key":"2025103104013056700_vkaf244-B17","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.3389\/fimmu.2019.02371","article-title":"Bacterial killing activity of polymorphonuclear myeloid-derived suppressor cells isolated from tumor-bearing dogs","volume":"10","author":"Hlavaty","year":"2019","journal-title":"Front Immunol"},{"key":"2025103104013056700_vkaf244-B18","doi-asserted-by":"crossref","first-page":"109912","DOI":"10.1016\/j.vetimm.2019.109912","article-title":"Characterization of myeloid-derived suppressor cells and cytokines GM-CSF, IL-10 and MCP-1 in dogs with malignant melanoma receiving a GD3-based immunotherapy","volume":"216","author":"Hutchison","year":"2019","journal-title":"Vet Immunol Immunopathol"},{"key":"2025103104013056700_vkaf244-B19","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1177\/0300985816634808","article-title":"Immunosuppression in dogs during mammary cancer development","volume":"53","author":"Mucha","year":"2016","journal-title":"Vet Pathol"},{"key":"2025103104013056700_vkaf244-B20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/1746-6148-8-209","article-title":"Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs","volume":"8","author":"Sherger","year":"2012","journal-title":"BMC Vet Res"},{"key":"2025103104013056700_vkaf244-B21","doi-asserted-by":"crossref","first-page":"110716","DOI":"10.1016\/j.vetimm.2024.110716","article-title":"Myeloid derived suppressor cells in peripheral blood can be a prognostic factor in canine transitional cell carcinoma","volume":"269","author":"Yokota","year":"2024","journal-title":"Vet Immunol Immunopathol"},{"key":"2025103104013056700_vkaf244-B22","doi-asserted-by":"crossref","first-page":"1162700","DOI":"10.3389\/fimmu.2023.1162700","article-title":"A single-cell RNA sequencing atlas of circulating leukocytes from healthy and osteosarcoma affected dogs","volume":"14","author":"Ammons","year":"2023","journal-title":"Front Immunol"},{"key":"2025103104013056700_vkaf244-B23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s42003-024-06182-w","article-title":"Single-cell RNA sequencing reveals the cellular and molecular heterogeneity of treatment-naive primary osteosarcoma in dogs","volume":"7","author":"Ammons","year":"2024","journal-title":"Commun Biol"},{"key":"2025103104013056700_vkaf244-B24","doi-asserted-by":"crossref","first-page":"1123366","DOI":"10.3389\/fimmu.2023.1123366","article-title":"Canine peripheral blood TCR\u03b1\u03b2 T cell atlas: identification of diverse subsets including CD8A(+) MAIT-like cells by combined single-cell transcriptome and V(D)J repertoire analysis","volume":"14","author":"Eschke","year":"2023","journal-title":"Front Immunol"},{"key":"2025103104013056700_vkaf244-B25","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.3390\/jcm8111802","article-title":"Characterization and potential applications of dog natural killer cells in cancer immunotherapy","volume":"8","author":"Gingrich","year":"2019","journal-title":"J Clin Med"},{"key":"2025103104013056700_vkaf244-B26","doi-asserted-by":"crossref","first-page":"670309","DOI":"10.3389\/fimmu.2021.670309","article-title":"Comparative immunogenomics of canine natural killer cells as immunotherapy target","volume":"12","author":"Gingrich","year":"2021","journal-title":"Front Immunol"},{"key":"2025103104013056700_vkaf244-B27","doi-asserted-by":"crossref","first-page":"1336158","DOI":"10.3389\/fvets.2024.1336158","article-title":"Improved characterization and translation of NK cells for canine immunotherapy","volume":"11","author":"Razmara","year":"2024","journal-title":"Front Vet Sci"},{"key":"2025103104013056700_vkaf244-B28","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1038\/s41598-023-50340-9","article-title":"Direct comparison of canine and human immune responses using transcriptomic and functional analyses","volume":"14","author":"Chow","year":"2024","journal-title":"Sci Rep"},{"key":"2025103104013056700_vkaf244-B29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/cancers12020418","article-title":"Ductal carcinoma in situ progression in dog model of breast cancer","volume":"12","author":"Mohammed","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025103104013056700_vkaf244-B30","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13058-023-01705-5","article-title":"Human basal-like breast cancer is represented by one of the two mammary tumor subtypes in dogs","volume":"25","author":"Watson","year":"2023","journal-title":"Breast Cancer Res"},{"key":"2025103104013056700_vkaf244-B31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/ilar\/ilu009","article-title":"Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology","volume":"55","author":"Fenger","year":"2014","journal-title":"ILAR J"},{"key":"2025103104013056700_vkaf244-B32","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1158\/1078-0432.CCR-24-1854","article-title":"Large-scale comparative analysis of canine and human osteosarcomas uncovers conserved clinically relevant tumor microenvironment subtypes","volume":"30","author":"Patkar","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025103104013056700_vkaf244-B33","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/ilar.51.3.208","article-title":"Cross talk from pets to people: translational osteosarcoma treatments","volume":"51","author":"Withrow","year":"2010","journal-title":"ILAR J"},{"key":"2025103104013056700_vkaf244-B34","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s42003-023-05208-z","article-title":"Transcriptional profiling of canine osteosarcoma identifies prognostic gene expression signatures with translational value for humans","volume":"6","author":"Mannheimer","year":"2023","journal-title":"Commun Biol"},{"key":"2025103104013056700_vkaf244-B35","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s42003-021-02683-0","article-title":"Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma","volume":"4","author":"Das","year":"2021","journal-title":"Commun Biol"},{"key":"2025103104013056700_vkaf244-B36","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/vco.12272","article-title":"Role of monocyte recruitment in hemangiosarcoma metastasis in dogs","volume":"15","author":"Regan","year":"2017","journal-title":"Vet Comp Oncol"},{"key":"2025103104013056700_vkaf244-B37","first-page":"1595","article-title":"Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin","volume":"1","author":"Kurzman","year":"1995","journal-title":"Clin Cancer Res"},{"key":"2025103104013056700_vkaf244-B38","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3109\/10611869408996814","article-title":"Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review","volume":"2","author":"MacEwen","year":"1994","journal-title":"J Drug Target"},{"key":"2025103104013056700_vkaf244-B39","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/1078-0432.CCR-21-2105","article-title":"Losartan blocks osteosarcoma-elicited monocyte recruitment, and combined with the kinase inhibitor toceranib, exerts significant clinical benefit in canine metastatic osteosarcoma","volume":"28","author":"Regan","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025103104013056700_vkaf244-B40","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.4049\/jimmunol.1800619","article-title":"The angiotensin receptor blocker losartan suppresses growth of pulmonary metastases via AT1R-independent inhibition of CCR2 signaling and monocyte recruitment","volume":"202","author":"Regan","year":"2019","journal-title":"J Immunol"},{"key":"2025103104013056700_vkaf244-B41","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1939-1676.2011.00883.x","article-title":"Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer","volume":"26","author":"Mitchell","year":"2012","journal-title":"J Vet Intern Med"},{"key":"2025103104013056700_vkaf244-B42","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/1535-7163.MCT-21-0726","article-title":"B7-H3 specific CAR T cells for the naturally occurring, spontaneous canine sarcoma model","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2025103104013056700_vkaf244-B43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00262-024-03642-4","article-title":"Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 co-expression on functional activity","volume":"73","author":"Cao","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"2025103104013056700_vkaf244-B44","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.rvsc.2010.12.012","article-title":"Cytokine-enhanced vaccine and interferon-beta plus suicide gene as combined therapy for spontaneous canine sarcomas","volume":"91","author":"Finocchiaro","year":"2011","journal-title":"Res Vet Sci"},{"key":"2025103104013056700_vkaf244-B45","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/jvim.15852","article-title":"Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin-2 administration results in long-term survival for companion dogs with osteosarcoma","volume":"34","author":"Flesner","year":"2020","journal-title":"J Vet Intern Med"},{"key":"2025103104013056700_vkaf244-B46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/vco.12642","article-title":"Safety evaluation of the canine osteosarcoma vaccine, live Listeria vector","volume":"19","author":"Musser","year":"2021","journal-title":"Vet Comp Oncol"},{"key":"2025103104013056700_vkaf244-B47","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.ymthe.2023.06.004","article-title":"A chimeric human\/dog-DNA vaccine against CSPG4 induces immunity with therapeutic potential in comparative preclinical models of osteosarcoma","volume":"31","author":"Tarone","year":"2023","journal-title":"Mol Ther"},{"key":"2025103104013056700_vkaf244-B48","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ccell.2020.01.004","article-title":"Comparative molecular life history of spontaneous canine and human gliomas","volume":"37","author":"Amin","year":"2020","journal-title":"Cancer Cell"},{"key":"2025103104013056700_vkaf244-B49","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/neuonc\/now051","article-title":"Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients","volume":"18","author":"LeBlanc","year":"2016","journal-title":"Neuro Oncol"},{"key":"2025103104013056700_vkaf244-B50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/cancers11020137","article-title":"Treatment combining CD200 immune checkpoint inhibitor and tumor-lysate vaccination after surgery for pet dogs with high-grade glioma","volume":"11","author":"Olin","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2025103104013056700_vkaf244-B51","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/1078-0432.CCR-19-2234","article-title":"CD200 checkpoint reversal: a novel approach to immunotherapy","volume":"26","author":"Xiong","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025103104013056700_vkaf244-B52","doi-asserted-by":"crossref","first-page":"e11074","DOI":"10.1371\/journal.pone.0011074","article-title":"Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial","volume":"5","author":"Xiong","year":"2010","journal-title":"PLoS One"},{"key":"2025103104013056700_vkaf244-B53","doi-asserted-by":"crossref","first-page":"e151239","DOI":"10.1172\/JCI151239","article-title":"Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas","volume":"132","author":"Ogino","year":"2022","journal-title":"J Clin Invest"},{"key":"2025103104013056700_vkaf244-B54","first-page":"423","article-title":"Evaluation of immunologic parameters in canine glioma patients treated with an oncolytic herpes virus","volume":"5","author":"Chambers","year":"2021","journal-title":"J Transl Genet Genom"},{"key":"2025103104013056700_vkaf244-B55","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1172\/JCI129502","article-title":"\u03b22 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells","volume":"129","author":"Mohammadpour","year":"2019","journal-title":"J Clin Invest"},{"key":"2025103104013056700_vkaf244-B56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00262-018-2243-8","article-title":"\u03b2-Adrenergic signaling blocks murine CD8(+) T-cell metabolic reprogramming during activation: a mechanism for immunosuppression by adrenergic stress","volume":"68","author":"Qiao","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2025103104013056700_vkaf244-B57","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1158\/2326-6066.CIR-20-0445","article-title":"Chronic adrenergic stress contributes to metabolic dysfunction and an exhausted phenotype in T cells in the tumor microenvironment","volume":"9","author":"Qiao","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"2025103104013056700_vkaf244-B58","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1158\/2767-9764.CRC-22-0388","article-title":"Reprogramming the canine glioma microenvironment with tumor vaccination plus oral losartan and propranolol induces objective responses","volume":"2","author":"Ammons","year":"2022","journal-title":"Cancer Res Commun"},{"key":"2025103104013056700_vkaf244-B59","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12032-023-02146-y","article-title":"Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy","volume":"40","author":"Dabas","year":"2023","journal-title":"Med Oncol"},{"key":"2025103104013056700_vkaf244-B60","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"2025103104013056700_vkaf244-B61","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3892\/mmr.2024.13171","article-title":"CAR-T cell therapy: a breakthrough in traditional cancer treatment strategies (review)","volume":"29","author":"Sun","year":"2024","journal-title":"Mol Med Rep"},{"key":"2025103104013056700_vkaf244-B62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.omto.2018.08.002","article-title":"Checkpoint blockade reverses anergy in IL-13R\u03b12 humanized scFv-based CAR T cells to treat murine and canine gliomas","volume":"11","author":"Yin","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"2025103104013056700_vkaf244-B63","doi-asserted-by":"crossref","first-page":"100905","DOI":"10.1016\/j.xpro.2021.100905","article-title":"Genetic re-direction of canine primary T cells for clinical trial use in pet dogs with spontaneous cancer","volume":"2","author":"Rotolo","year":"2021","journal-title":"STAR Protoc"},{"key":"2025103104013056700_vkaf244-B64","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/mt.2016.146","article-title":"Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma","volume":"24","author":"Panjwani","year":"2016","journal-title":"Mol Ther"},{"key":"2025103104013056700_vkaf244-B65","doi-asserted-by":"crossref","first-page":"1676615","DOI":"10.1080\/2162402X.2019.1676615","article-title":"Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma","volume":"9","author":"Panjwani","year":"2020","journal-title":"Oncoimmunology"},{"key":"2025103104013056700_vkaf244-B66","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/vco.12197","article-title":"Immune regulation of canine tumour and macrophage PD-L1 expression","volume":"15","author":"Hartley","year":"2017","journal-title":"Vet Comp Oncol"},{"key":"2025103104013056700_vkaf244-B67","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/vco.12829","article-title":"Long-term survival of dogs with stage 4 oral malignant melanoma treated with anti-canine PD-1 therapeutic antibody: a follow-up case report","volume":"20","author":"Igase","year":"2022","journal-title":"Vet Comp Oncol"},{"key":"2025103104013056700_vkaf244-B68","doi-asserted-by":"crossref","first-page":"18311","DOI":"10.1038\/s41598-020-75533-4","article-title":"A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs","volume":"10","author":"Igase","year":"2020","journal-title":"Sci Rep"},{"key":"2025103104013056700_vkaf244-B69","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41698-021-00147-6","article-title":"PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma","volume":"5","author":"Maekawa","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"2025103104013056700_vkaf244-B70","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.vetimm.2018.02.007","article-title":"Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1","volume":"198","author":"Nemoto","year":"2018","journal-title":"Vet Immunol Immunopathol"},{"key":"2025103104013056700_vkaf244-B71","first-page":"195","article-title":"Programmed cell death ligand 1 expression in canine cancer","volume":"30","author":"Shosu","year":"2016","journal-title":"In Vivo"},{"key":"2025103104013056700_vkaf244-B72","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1177\/03009858211011939","article-title":"PD-1, PD-L1, and PD-L2 gene expression and tumor infiltrating lymphocytes in canine melanoma","volume":"58","author":"Stevenson","year":"2021","journal-title":"Vet Pathol"},{"key":"2025103104013056700_vkaf244-B73","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/vco.12294","article-title":"PD-1 expression by canine T cells and functional effects of PD-1 blockade","volume":"15","author":"Coy","year":"2017","journal-title":"Vet Comp Oncol"},{"key":"2025103104013056700_vkaf244-B74","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/ilar\/ilu017","article-title":"Domestic dogs and cancer research: a breed-based genomics approach","volume":"55","author":"Davis","year":"2014","journal-title":"ILAR J"},{"key":"2025103104013056700_vkaf244-B75","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1146\/annurev-animal-030117-014523","article-title":"Canine cancer genomics: lessons for canine and human health","volume":"7","author":"Ostrander","year":"2019","journal-title":"Annu Rev Anim Biosci"},{"key":"2025103104013056700_vkaf244-B76","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3389\/fonc.2019.01493","article-title":"Naturally-occurring invasive urothelial carcinoma in dogs, a unique model to drive advances in managing muscle invasive bladder cancer in humans","volume":"9","author":"Knapp","year":"2019","journal-title":"Front Oncol"},{"key":"2025103104013056700_vkaf244-B77","doi-asserted-by":"crossref","first-page":"106044","DOI":"10.1016\/j.tvjl.2023.106044","article-title":"Association between cigarette smoke exposure and urinary bladder cancer in Scottish terriers in a cohort study","volume":"303","author":"Knapp","year":"2024","journal-title":"Vet J"},{"key":"2025103104013056700_vkaf244-B78","first-page":"231","article-title":"Comparative aspects of BRAF mutations in canine cancers","volume":"2","author":"Mochizuki","year":"2015","journal-title":"Vet Sci"},{"key":"2025103104013056700_vkaf244-B79","doi-asserted-by":"crossref","first-page":"6589529","DOI":"10.1155\/2017\/6589529","article-title":"Naturally occurring canine invasive urinary bladder cancer: a complementary animal model to improve the success rate in human clinical trials of new cancer drugs","volume":"2017","author":"Fulkerson","year":"2017","journal-title":"Int J Genomics."},{"key":"2025103104013056700_vkaf244-B80","doi-asserted-by":"crossref","first-page":"1033704","DOI":"10.3389\/fonc.2022.1033704","article-title":"Canine oral squamous cell carcinoma as a spontaneous, translational model for radiation and immunology research","volume":"12","author":"Boss","year":"2022","journal-title":"Front Oncol"},{"key":"2025103104013056700_vkaf244-B81","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.neo.2020.10.003","article-title":"Molecular homology between canine spontaneous oral squamous cell carcinomas and human head-and-neck squamous cell carcinomas reveals disease drivers and therapeutic vulnerabilities","volume":"22","author":"Guscetti","year":"2020","journal-title":"Neoplasia"},{"key":"2025103104013056700_vkaf244-B82","doi-asserted-by":"crossref","first-page":"e1005277","DOI":"10.1371\/journal.pgen.1005277","article-title":"Canine spontaneous head and neck squamous cell carcinomas represent their human counterparts at the molecular level","volume":"11","author":"Liu","year":"2015","journal-title":"PLoS Genet"},{"key":"2025103104013056700_vkaf244-B83","doi-asserted-by":"crossref","first-page":"109637","DOI":"10.1016\/j.clim.2023.109637","article-title":"OX40 shapes an inflamed tumor immune microenvironment and predicts response to immunochemotherapy in diffuse large B-cell lymphoma","volume":"251","author":"Lu","year":"2023","journal-title":"Clin Immunol"},{"key":"2025103104013056700_vkaf244-B84","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3390\/vaccines12121341","article-title":"Challenges and new directions in therapeutic cancer vaccine development","volume":"12","author":"Pan","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"2025103104013056700_vkaf244-B85","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-24-2770","article-title":"A phase I clinical trial adding OX40 agonism to in situ therapeutic cancer vaccination in patients with low-grade B cell lymphoma highlights challenges in translation from mouse to human studies","volume":"31","author":"Shree","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2025103104013056700_vkaf244-B86","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1172\/JCI128562","article-title":"In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors","volume":"129","author":"Khalil","year":"2019","journal-title":"J Clin Invest"},{"key":"2025103104013056700_vkaf244-B87","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/ijms23020826","article-title":"Immunologic effects of stereotactic body radiotherapy in dogs with spontaneous tumors and the impact of intratumoral OX40\/TLR agonist immunotherapy","volume":"23","author":"Boss","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025103104013056700_vkaf244-B88","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00262-025-03950-3","article-title":"Characterization of canine tumor-infiltrating leukocyte transcriptomic signatures reveals conserved expression patterns with human osteosarcoma","volume":"74","author":"Ammons","year":"2025","journal-title":"Cancer Immunol Immunother"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/214\/10\/2515\/65038805\/vkaf244.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/214\/10\/2515\/65038805\/vkaf244.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:01:49Z","timestamp":1761897709000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/214\/10\/2515\/8306509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":88,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,31]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jimmun\/vkaf244","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10,1]]}}}